Press Releases Altimmune, Inc.

Equities

ALT

US02155H2004

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2025-07-08 EDT			After hours 19:37:06
4.580 ^USD	+3.39%		4.540	-0.87%

06-30	Altimmune, Inc.(NasdaqGM:ALT) dropped from Russell 3000E Value Index	CI
06-30	Altimmune, Inc.(NasdaqGM:ALT) dropped from Russell 3000 Value Index	CI

Press Releases

Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT	07-07	PR
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT	07-02	PR
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT	06-27	PR
Altimmune Announces Positive Topline Results from the IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH	06-26	AQ
Altimmune to Announce Topline 24 Week Results from its IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH on Thursday, June 26	06-25	AQ
Altimmune Announces Multiple Presentations at Upcoming American Diabetes Association’s Scientific Sessions	06-13	AQ
Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder (AUD)	05-19	AQ
Altimmune to Participate at Two Upcoming Investor Conferences	05-14	AQ
Altimmune Secures Up to $100 Million in Credit Facility from Hercules Capital	05-13	AQ
Altimmune Announces First Quarter 2025 Financial Results and Business Update	05-13	AQ
Poster: MASH resolution index, a novel, highly sensitive non-invasive measure of histologic improvement, predicts high rates of MASH resolution with pemvidutide treatment of metabolic dysfunction-associated steatohepatitis (MASH)	05-08	PU
Altimmune Presents New Analyses Predicting High Rates of MASH Resolution on Biopsy following Pemvidutide Treatment at the EASL International Liver Congress™	05-08	AQ
Altimmune to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025	05-06	AQ
Altimmune to Present at Upcoming EASL International Liver Congress 2025	05-02	AQ
Altimmune to Present at Upcoming EASL International Liver Congress™ 2025	05-01	AQ
Altimmune to Participate in the Citizens Life Sciences Conference	04-30	AQ
Altimmune to Host Virtual R&D Day on March 13, 2025	03-06	AQ
Altimmune to Participate in the Leerink Global Healthcare Conference	03-03	AQ
Altimmune Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update	02-27	AQ
Seasoned Biopharmaceutical Industry Executives Teri Lawver and Jerry Durso Appointed to Altimmune Board of Directors	02-25	AQ
Altimmune to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on February 27, 2025	02-20	AQ
Altimmune to Participate in the Guggenheim SMID Cap Biotech Conference	01-29	AQ
Altimmune Added to Nasdaq Biotechnology Index	12-19	AQ
Altimmune to Present at the Cachexia Regulatory and Trials Update Workshop of the 17th International Conference of the Society on Sarcopenia, Cachexia and Wasting Disorders	12-03	AQ
Altimmune to Present at the Cachexia Regulatory & Trials Update Workshop of the 17th International Conference of the Society on Sarcopenia, Cachexia & Wasting Disorders	12-02	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Altimmune, Inc.

Equities

ALT

US02155H2004

Biotechnology & Medical Research

Press Releases

Filters